Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AmerisourceBergen to buy PharMEDium for $2.58 billion

Drug distributor AmerisourceBergen Corp agreed to buy PharMEDium Healthcare Holdings Inc for $2.58 billion from private equity firm Clayton, Dubilier & Rice, expanding its business of supplying compounded drugs to hospitals. Compounding is a process in which pharma products are diluted to create doses that are not sold commercially. Increased regulatory oversight following a fungal […]

Read More »

Valeant Under Fire Again Following New York Times Article

NEW YORK – A New York Times article excoriated Valeant Pharmaceuticals International, Inc. (VRX) for the amount the company spends on research and development versus the amount it spends on mergers and acquisitions after the Quebec-based company quadrupled the price on a 55-year-old drug that treats Wilson Disease, a genetic disorder.   The Times highlights […]

Read More »

U.S. says it will not fight Steris loss in district court

U.S. antitrust enforcers will not appeal a court ruling that said U.S. medical technology provider Steris Corp could proceed with a merger with British sterilization services provider Synergy Health Plc, a Federal Trade Commission spokesman said on Thursday. The FTC filed a lawsuit in May aimed at stopping the proposed transaction, saying it would hurt […]

Read More »

Teva Accelerates its Emerging Markets Growth Strategy with the Acquisition of Rimsa, a Leading Independent Pharmaceutical Company in Mexico with a Portfolio of Products and Patents in Latin America

Strategic Move Enhances Teva’s Presence in Mexico, the Second Largest Market in Latin America and a Major Emerging Market Brings a Portfolio of Differentiated, Patent-Protected, Fixed-Dose Medicine Combinations, Strong Brand and Commercial Presence and Loyal Customer Base October 01, 2015 08:00 AM Eastern Daylight Time   JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) […]

Read More »

Troubled XOMA Nails Immuno-Oncology Pact Worth $530 Million+ With Novartis

BERKELEY, Calif. – Swiss-based Novartis AG (NVS) struck a deal worth more than $500 million with XOMA Corporation (XOMA) to acquire rights to the company’s anti-transforming growth factor-beta (TGFb) antibody program, Xoma announced this morning. Under terms of the deal, Xoma will receive $37 million in upfront payments, with the remaining $480 million in regulatory […]

Read More »

Germany’s Merck sells rights to Kuvan back to BioMarin Pharma

Germany’s Merck KGaA said it agreed to return to BioMarin Pharmaceutical Inc the rights to the Kuvan drug against rare genetic disorder PKU as it seeks to focus on cancer, immunology and neurology. Merck in 2005 acquired the rights to Kuvan and Peg-Pal, another PKU treatment, outside the United States and Japan. Under the agreement […]

Read More »

Amgen’s leukemia drug gets conditional European approval

European health regulators on Friday conditionally approved Amgen Inc’s rare blood cancer drug, Blincyto, which is one of the world’s most expensive cancer treatments. The U.S. Food and Drug Administration in December approved Blincyto for acute lymphoblastic leukemia (ALL), which has few treatment options once a patient has relapsed. Blincyto is a so-called bispecific antibody, […]

Read More »

AbbVie scraps Galapagos deal to focus on own arthritis drug

AbbVie Inc said its experimental drug improved symptoms of rheumatoid arthritis in mid-stage studies and scrapped plans to buy rights to a similar treatment from Belgium’s Galapagos NV. Galapagos shares were down 27 percent at 40.20 euros in Amsterdam. AbbVie shares rose 2 percent to $57.66 in early trading on Friday. Analysts said the drug’s […]

Read More »

FDA advisers to weigh concerns over Bayer’s Essure contraceptive

U.S. health experts will review the potential risks of Bayer AG’s permanent contraceptive device, Essure, on Thursday in light of growing complaints over possible side effects, and consider whether its use should be restricted.   The Food and Drug Administration made public on Tuesday the questions it would like addressed by an advisory panel of […]

Read More »

AstraZeneca PLC Makes Large Data Set Available to Outside Scientists to Find Cancer Drug Cocktails

LONDON – AstraZeneca will release preclinical data from more than 50 medicines in an effort to find new cancer treatments as part of a new challenge to tap the minds of researchers and clinicians across the globe. AstraZeneca’s decision is part of a crowd-sourcing effort to accelerate the development for “synergistic tumor-fighting drug combinations,” Reuters […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom